Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC? episode artwork

EPISODE · Oct 6, 2015 · 7 MIN

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?

from GRACEcast · host cancerGRACE Meetings

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

Episode metadata supplied by the publisher feed · Published Oct 6, 2015

Embed this episode

NOW PLAYING

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?

0:00 7:48

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 7 minutes long.

When was this GRACEcast episode published?

This episode was published on October 6, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!